SG11201507380PA - Novel inhibitor compounds of phosphodiesterase type 10a - Google Patents

Novel inhibitor compounds of phosphodiesterase type 10a

Info

Publication number: SG11201507380PA
Authority: SG; Singapore
Prior art keywords: inhibitor compounds; phosphodiesterase type; novel inhibitor; novel; phosphodiesterase
Prior art date: 2013-03-13

Application number

SG11201507380PA

Inventor

Katja Jantos

Michael Ochse

Hervé Geneste

Jayne Froggett

Clarissa Jakob

Karla Drescher

Jürgen Dinges

Original Assignee

Abbvie Deutschland

Abbvie Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-13

Filing date

2014-03-12

Publication date

2015-10-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50241454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201507380P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-03-12 Application filed by Abbvie Deutschland, Abbvie Inc filed Critical Abbvie Deutschland

2015-10-29 Publication of SG11201507380PA publication Critical patent/SG11201507380PA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Epidemiology (AREA)

SG11201507380PA 2013-03-13 2014-03-12 Novel inhibitor compounds of phosphodiesterase type 10a SG11201507380PA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361779141P	2013-03-13	2013-03-13
PCT/EP2014/054810 WO2014140086A1 (en)	2013-03-13	2014-03-12	Novel inhibitor compounds of phosphodiesterase type 10a

Publications (1)

Publication Number	Publication Date
SG11201507380PA true SG11201507380PA (en)	2015-10-29

Family

ID=50241454

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201507380PA SG11201507380PA (en)	2013-03-13	2014-03-12	Novel inhibitor compounds of phosphodiesterase type 10a

Country Status (22)

Country	Link
US (1)	US9200005B2 (en)
EP (1)	EP2970328B1 (en)
JP (1)	JP2016510786A (en)
KR (1)	KR20150127724A (en)
CN (1)	CN105358561A (en)
AR (1)	AR095267A1 (en)
AU (1)	AU2014230825A1 (en)
BR (1)	BR112015022094A2 (en)
CA (1)	CA2902654A1 (en)
CL (1)	CL2015002545A1 (en)
CR (1)	CR20150496A (en)
DO (1)	DOP2015000214A (en)
HK (1)	HK1219273A1 (en)
IL (1)	IL240593A0 (en)
MX (1)	MX2015012389A (en)
PE (1)	PE20160040A1 (en)
PH (1)	PH12015501962A1 (en)
RU (1)	RU2015143536A (en)
SG (1)	SG11201507380PA (en)
TW (1)	TW201441230A (en)
UY (1)	UY35393A (en)
WO (1)	WO2014140086A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20161035A1 (en)	2013-03-15	2016-11-13	Global Blood Therapeutics Inc	COMPOUNDS AND USES OF THESE FOR THE MODULATION OF HEMOGLOBIN
EA201992707A1 (en)	2013-11-18	2020-06-30	Глобал Блад Терапьютикс, Инк.	COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
JP6814730B2 (en)	2014-09-05	2021-01-20	ジェネンテック，インコーポレイテッド	Therapeutic compounds and their use
WO2016036954A1 (en) *	2014-09-05	2016-03-10	Genentech, Inc.	Phthalazine derivatives of formula (i) as pcaf and gcn5 inhibitors for use in the treatment of cancer
EP3242874B1 (en)	2015-01-09	2018-10-31	Genentech, Inc.	Pyridazinone derivatives and their use in the treatment of cancer
CA3067591A1 (en) *	2017-06-28	2019-01-03	Ptc Therapeutics, Inc.	Methods for treating huntington's disease
CN115838364A (en) *	2022-12-20	2023-03-24	河南沁朋科技有限公司	Synthetic method of 3, 3-bithiophene
TW202506660A (en) *	2023-04-27	2025-02-16	美商塞普特納公司	Mrgprx2 antagonists and methods of use thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69807741T2 (en) *	1997-12-05	2004-07-15	Astrazeneca Uk Ltd.	NEW CONNECTIONS
US20030032579A1 (en)	2001-04-20	2003-02-13	Pfizer Inc.	Therapeutic use of selective PDE10 inhibitors
SE0300120D0 (en) *	2003-01-17	2003-01-17	Astrazeneca Ab	Novel compounds
US20070032404A1 (en)	2003-07-31	2007-02-08	Bayer Pharmaceuticals Corporation	Methods for treating diabetes and related disorders using pde10a inhibitors
JP2008501776A (en)	2004-06-07	2008-01-24	ファイザー・プロダクツ・インク	Inhibition of phosphodiesterase 10 as a treatment for conditions associated with obesity and associated with metabolic syndrome
AU2005282721A1 (en)	2004-09-03	2006-03-16	Memory Pharmaceuticals Corporation	4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
EP1940819A1 (en)	2005-08-16	2008-07-09	Memory Pharmaceuticals Corporation	Phosphodiesterase 10 inhibitors
NL2000397C2 (en)	2006-01-05	2007-10-30	Pfizer Prod Inc	Bicyclic heteroaryl compounds as PDE10 inhibitors.
WO2007082546A1 (en)	2006-01-20	2007-07-26	H. Lundbeck A/S	Use of tofisopam as a pde10a inhibitor
BRPI0707223A2 (en)	2006-01-27	2011-04-26	Pfizer Prod Inc	aminophthalazine derivative compounds
EP1991540A1 (en)	2006-02-21	2008-11-19	Amgen Inc.	Cinnoline derivatives as phosphodiesterase 10 inhibitors
AU2007217750A1 (en)	2006-02-21	2007-08-30	Amgen Inc.	Cinnoline derivatives as phosphodiesterase 10 inhibitors
JP2009527542A (en)	2006-02-23	2009-07-30	ファイザー・プロダクツ・インク	Substituted quinazolines as PDE10 inhibitors
EP1991531A1 (en)	2006-02-28	2008-11-19	Amgen Inc.	Cinnoline and quinoxaline derivates as phosphodiesterase 10 inhibitors
US20070265258A1 (en)	2006-03-06	2007-11-15	Ruiping Liu	Quinazoline derivatives as phosphodiesterase 10 inhibitors
AU2007223801A1 (en)	2006-03-08	2007-09-13	Amgen Inc.	Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
TW200817400A (en)	2006-05-30	2008-04-16	Elbion Ag	Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
TW200815436A (en)	2006-05-30	2008-04-01	Elbion Ag	4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
CA2654394A1 (en)	2006-06-26	2008-01-03	Pfizer Products Inc.	Tricyclic heteroaryl compounds as pde10 inhibitors
US20080090834A1 (en)	2006-07-06	2008-04-17	Pfizer Inc	Selective azole pde10a inhibitor compounds
US8492394B2 (en)	2006-07-10	2013-07-23	H. Lundbeck A/S	(3-aryl-piperazin-1-yl), (2-aryl-morpholin-4-yl) and (2-aryl-thiomorpholin-4-yl) derivatives of 6,7-dialkoxy-quinazoline, 6,7-dialkoxyphtalazine and 6,7-dialkoxyisoquinoline as PDE10A enzyme inhibitors
WO2008020302A2 (en)	2006-08-17	2008-02-21	Pfizer Products Inc.	Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
WO2009025823A1 (en)	2007-08-21	2009-02-26	Amgen Inc.	Phosphodiesterase 10 inhibitors
US20090062291A1 (en)	2007-08-22	2009-03-05	Essa Hu	Phosphodiesterase 10 inhibitors
WO2009029214A1 (en)	2007-08-23	2009-03-05	Amgen Inc.	Isoquinolone derivatives as phosphodiesterase 10 inhibitors
TW200918519A (en)	2007-09-19	2009-05-01	Lundbeck & Co As H	Cyanoisoquinoline
JP2011505366A (en)	2007-11-30	2011-02-24	ワイス・エルエルシー	Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphoesterase 10
US20090143392A1 (en)	2007-11-30	2009-06-04	Elbion Gmbh	Methods of Treating Obesity and Metabolic Disorders
US20090143361A1 (en)	2007-11-30	2009-06-04	Elbion Gmbh	Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
WO2009068320A1 (en)	2007-11-30	2009-06-04	Elbion Gmbh	Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
WO2009076454A2 (en) *	2007-12-12	2009-06-18	Calcimedica, Inc.	Compounds that modulate intracellular calcium
US8927718B2 (en) *	2009-08-26	2015-01-06	Takeda Pharmaceutical Company Limited	Fused heterocyclic ring derivative and use thereof
US20130203756A1 (en)	2010-10-29	2013-08-08	Jamie L. Bunda	Isoindoline pde10 inhibitors
US9938269B2 (en)	2011-06-30	2018-04-10	Abbvie Inc.	Inhibitor compounds of phosphodiesterase type 10A
US20130116241A1 (en)	2011-11-09	2013-05-09	Abbvie Inc.	Novel inhibitor compounds of phosphodiesterase type 10a

2014
- 2014-02-25 US US14/189,961 patent/US9200005B2/en not_active Expired - Fee Related
- 2014-03-12 BR BR112015022094A patent/BR112015022094A2/en not_active IP Right Cessation
- 2014-03-12 PE PE2015001893A patent/PE20160040A1/en not_active Application Discontinuation
- 2014-03-12 MX MX2015012389A patent/MX2015012389A/en unknown
- 2014-03-12 AU AU2014230825A patent/AU2014230825A1/en not_active Abandoned
- 2014-03-12 TW TW103108560A patent/TW201441230A/en unknown
- 2014-03-12 HK HK16107260.0A patent/HK1219273A1/en unknown
- 2014-03-12 UY UY0001035393A patent/UY35393A/en not_active Application Discontinuation
- 2014-03-12 WO PCT/EP2014/054810 patent/WO2014140086A1/en not_active Ceased
- 2014-03-12 SG SG11201507380PA patent/SG11201507380PA/en unknown
- 2014-03-12 AR ARP140100879A patent/AR095267A1/en unknown
- 2014-03-12 CA CA2902654A patent/CA2902654A1/en not_active Abandoned
- 2014-03-12 RU RU2015143536A patent/RU2015143536A/en unknown
- 2014-03-12 EP EP14709320.7A patent/EP2970328B1/en not_active Not-in-force
- 2014-03-12 JP JP2015562117A patent/JP2016510786A/en active Pending
- 2014-03-12 KR KR1020157029132A patent/KR20150127724A/en not_active Withdrawn
- 2014-03-12 CN CN201480014146.XA patent/CN105358561A/en active Pending
2015
- 2015-08-16 IL IL240593A patent/IL240593A0/en unknown
- 2015-09-03 DO DO2015000214A patent/DOP2015000214A/en unknown
- 2015-09-04 PH PH12015501962A patent/PH12015501962A1/en unknown
- 2015-09-09 CL CL2015002545A patent/CL2015002545A1/en unknown
- 2015-09-16 CR CR20150496A patent/CR20150496A/en unknown

Also Published As

Publication number	Publication date
HK1219273A1 (en)	2017-03-31
CA2902654A1 (en)	2014-09-18
US20140275069A1 (en)	2014-09-18
DOP2015000214A (en)	2015-12-31
IL240593A0 (en)	2015-09-24
WO2014140086A1 (en)	2014-09-18
PE20160040A1 (en)	2016-02-11
US9200005B2 (en)	2015-12-01
PH12015501962A1 (en)	2016-01-11
KR20150127724A (en)	2015-11-17
UY35393A (en)	2014-10-31
MX2015012389A (en)	2016-03-03
AU2014230825A1 (en)	2015-09-03
CL2015002545A1 (en)	2016-07-22
JP2016510786A (en)	2016-04-11
RU2015143536A (en)	2017-04-18
EP2970328A1 (en)	2016-01-20
CR20150496A (en)	2016-02-19
EP2970328B1 (en)	2017-04-26
BR112015022094A2 (en)	2018-06-12
CN105358561A (en)	2016-02-24
TW201441230A (en)	2014-11-01
AR095267A1 (en)	2015-09-30

Publication	Publication Date	Title
IL279682A (en)	2021-03-01	Benzoquinolone inhibitors of vmat2
EP2948450A4 (en)	2016-11-09	Metalloenzyme inhibitor compounds
IL243579A0 (en)	2016-02-29	Polymorph of syk inhibitors
ZA201506156B (en)	2017-11-29	Novel inhibitors
GB201317609D0 (en)	2013-11-20	Inhibitor compounds
IL240593A0 (en)	2015-09-24	Novel inhibitor compounds of phosphodiesterase type 10a
IL243295A0 (en)	2016-02-29	Carbazole carboxamide compounds useful as kinase inhibitors
IL244617A0 (en)	2016-04-21	Benzoquinolone inhibitors of vmat2
IL240763A0 (en)	2015-10-29	Halogenopyrazoles as inhibitors of therombin
IL237626A0 (en)	2015-04-30	Novel inhibitor compounds of phosphodiesterase type 10a
ZA201507100B (en)	2017-03-29	Synthesis of bace1 inhibitors
HUE041421T2 (en)	2019-05-28	Composition of tiacumicin compounds
IL238739A0 (en)	2015-06-30	Novel inhibitor compounds of phosphodiesterase type 10a
TWI562990B (en)	2016-12-21	Novel compounds as inhibitors of janus kinase
GB2523615B (en)	2016-06-15	Use of Naphthalene-1,4-diketone compound as hCBS enzyme inhibitor
EP2959896A4 (en)	2016-08-17	Inhibitor of tprotein phosphorylation
IL236946A0 (en)	2015-03-31	Inhibitor compounds of phosphodiesterase type 10a
GB201321328D0 (en)	2014-01-15	Inhibitor compounds
GB201323021D0 (en)	2014-02-12	Use of kinase inhibitors
GB201321227D0 (en)	2014-01-15	Use of kinase inhibitors
GB201309603D0 (en)	2013-07-10	Novel compounds and their use as kinase inhibitors
GB201305741D0 (en)	2013-05-15	Novel compounds and their use as kinase inhibitors
GB201305503D0 (en)	2013-05-08	Inhibitor